Introduction:
The pharmaceutical industry in Japan continues to thrive, with a growing emphasis on biologics as a key area of focus. In 2025, the production volume of biologics in Japan reached a record high, driving significant market growth and exports. As we look ahead to 2026, it is crucial to identify the top 10 importers of biologics in Japan to gain insights into market trends and opportunities.
Top 10 Biologics Importers in Japan 2026:
1. Pfizer Inc.
With a market share of 15%, Pfizer Inc. remains a dominant player in the biologics market in Japan. The company’s innovative biologic products continue to be in high demand, driving their import volume significantly.
2. Roche Holding AG
Roche Holding AG holds a strong position as one of the top biologics importers in Japan, with a market share of 12%. Their diverse portfolio of biologic therapies caters to various medical needs, contributing to their import success.
3. Novartis International AG
Novartis International AG has secured the third spot among the top biologics importers in Japan, with a market share of 10%. The company’s commitment to research and development has led to the successful import of cutting-edge biologic treatments.
4. Johnson & Johnson
Johnson & Johnson has established itself as a key player in the Japanese biologics market, with a market share of 8%. Their strategic partnerships and investment in biologic innovation have propelled their import volume.
5. AbbVie Inc.
AbbVie Inc. ranks fifth among the top biologics importers in Japan, with a market share of 7%. The company’s focus on specialty biologic therapies has resonated well with the Japanese market, driving their import success.
6. Amgen Inc.
Amgen Inc. has made significant strides in the Japanese biologics market, securing the sixth position with a market share of 6%. Their portfolio of biologic products for oncology and chronic diseases has garnered widespread recognition and import demand.
7. AstraZeneca PLC
AstraZeneca PLC has emerged as a key importer of biologics in Japan, with a market share of 5%. The company’s innovative biologic treatments for respiratory and cardiovascular diseases have contributed to their import growth.
8. Merck & Co., Inc.
Merck & Co., Inc. holds a strong position as a biologics importer in Japan, with a market share of 4%. Their focus on biologic research and development has led to the successful import of groundbreaking therapies for various medical conditions.
9. Bristol Myers Squibb
Bristol Myers Squibb ranks ninth among the top biologics importers in Japan, with a market share of 3%. The company’s biologic treatments for cancer and autoimmune diseases have gained popularity in the Japanese market, driving their import volume.
10. Gilead Sciences, Inc.
Gilead Sciences, Inc. rounds out the top 10 biologics importers in Japan, with a market share of 2%. The company’s innovative biologic therapies for HIV/AIDS and liver diseases have contributed to their import success in the Japanese market.
Insights:
Looking ahead to 2026, the Japanese biologics market is poised for continued growth, driven by increasing demand for innovative biologic treatments. With a focus on research and development, top importers like Pfizer Inc., Roche Holding AG, and Novartis International AG are expected to maintain their strong presence in the market. Additionally, collaborations and partnerships within the industry are likely to fuel further import growth. By staying ahead of market trends and investing in cutting-edge biologic therapies, importers can capitalize on the growing opportunities in the Japanese biologics market.
Related Analysis: View Previous Industry Report
